X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with Orchid Chemicals - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs ORCHID PHARMA LTD - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

ORCHID PHARMA LTD 
   Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS ORCHID PHARMA LTD NOVARTIS/
ORCHID PHARMA LTD
 
P/E (TTM) x 295.1 0.2 151,768.9% View Chart
P/BV x 25.1 0.2 10,922.2% View Chart
Dividend Yield % 1.5 0.0 -  

Financials

 NOVARTIS   ORCHID PHARMA LTD
EQUITY SHARE DATA
    NOVARTIS
Mar-17
ORCHID PHARMA LTD
Sep-13
NOVARTIS/
ORCHID PHARMA LTD
5-Yr Chart
Click to enlarge
High Rs855194 440.7%   
Low Rs66635 1,901.7%   
Sales per share (Unadj.) Rs219.0276.5 79.2%  
Earnings per share (Unadj.) Rs19.1-79.2 -24.1%  
Cash flow per share (Unadj.) Rs20.3-43.5 -46.7%  
Dividends per share (Unadj.) Rs10.000-  
Dividend yield (eoy) %1.30-  
Book value per share (Unadj.) Rs307.053.9 569.1%  
Shares outstanding (eoy) m29.9670.45 42.5%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.50.4 838.1%   
Avg P/E ratio x39.8-1.4 -2,753.9%  
P/CF ratio (eoy) x37.5-2.6 -1,421.5%  
Price / Book Value ratio x2.52.1 116.7%  
Dividend payout %52.40-   
Avg Mkt Cap Rs m22,7798,067 282.4%   
No. of employees `0000.72.8 24.1%   
Total wages/salary Rs m1,3932,527 55.1%   
Avg. sales/employee Rs Th9,736.26,956.1 140.0%   
Avg. wages/employee Rs Th2,066.8902.5 229.0%   
Avg. net profit/employee Rs Th849.0-1,993.0 -42.6%   
INCOME DATA
Net Sales Rs m6,56219,477 33.7%  
Other income Rs m702407 172.3%   
Total revenues Rs m7,26419,884 36.5%   
Gross profit Rs m2591,103 23.5%  
Depreciation Rs m362,519 1.4%   
Interest Rs m75,227 0.1%   
Profit before tax Rs m917-6,236 -14.7%   
Minority Interest Rs m020 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0511 0.0%   
Tax Rs m345-125 -275.6%   
Profit after tax Rs m572-5,580 -10.3%  
Gross profit margin %3.95.7 69.7%  
Effective tax rate %37.62.0 1,873.9%   
Net profit margin %8.7-28.7 -30.4%  
BALANCE SHEET DATA
Current assets Rs m9,73111,014 88.4%   
Current liabilities Rs m1,83032,060 5.7%   
Net working cap to sales %120.4-108.1 -111.4%  
Current ratio x5.30.3 1,547.5%  
Inventory Days Days4995 51.3%  
Debtors Days Days2534 75.0%  
Net fixed assets Rs m5729,440 0.2%   
Share capital Rs m141705 20.0%   
"Free" reserves Rs m9,0562,043 443.3%   
Net worth Rs m9,1963,800 242.0%   
Long term debt Rs m09,018 0.0%   
Total assets Rs m11,49946,510 24.7%  
Interest coverage x128.4-0.2 -66,488.6%   
Debt to equity ratio x02.4 0.0%  
Sales to assets ratio x0.60.4 136.3%   
Return on assets %5.0-0.8 -662.9%  
Return on equity %6.2-146.9 -4.2%  
Return on capital %10.1-3.7 -269.2%  
Exports to sales %037.9 0.0%   
Imports to sales %022.6 0.0%   
Exports (fob) Rs mNA7,378 0.0%   
Imports (cif) Rs mNA4,406 0.0%   
Fx inflow Rs m1297,513 1.7%   
Fx outflow Rs m1,7345,649 30.7%   
Net fx Rs m-1,6051,865 -86.1%   
CASH FLOW
From Operations Rs m-3801,682 -22.6%  
From Investments Rs m4,208-9,860 -42.7%  
From Financial Activity Rs m-3,3186,644 -49.9%  
Net Cashflow Rs m510-1,535 -33.2%  

Share Holding

Indian Promoters % 0.0 32.3 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 4.6 43.5%  
FIIs % 1.6 3.3 48.5%  
ADR/GDR % 0.0 4.6 -  
Free float % 21.5 55.3 38.9%  
Shareholders   41,647 84,811 49.1%  
Pledged promoter(s) holding % 0.0 54.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   BIOCON LTD  CADILA HEALTHCARE  SUVEN LIFE  PLETHICO PHARMA  WOCKHARDT LTD.  

Compare NOVARTIS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Volatile Day in Red; Pharma Stocks Lose Most(Closing)

After opening the day in green, share markets in India witnessed volatile trading activity throughout the day and ended the day on a negative note.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Jun 21, 2018 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS - LUPIN LTD COMPARISON

COMPARE NOVARTIS WITH

MARKET STATS